Grifols (GRFS) Cash & Current Investments (2009 - 2025)

Grifols (GRFS) posted Cash & Current Investments of $965.0 million for Q4 2025, down 8.41% quarter-over-quarter from $1.1 billion in Q4 2024, and down 8.41% year-on-year from $1.1 billion in Q4 2024.

Grifols (GRFS) Cash & Current Investments (2009 - 2025) Analysis & Trends

Grifols (GRFS) has reported Cash & Current Investments for 16 consecutive years, with $965.0 million the latest figure, recorded in Q4 2025.

  • Cash & Current Investments for Q4 2025 came in at $965.0 million, down 8.41% year-over-year; the trailing twelve-month figure through Dec 2025 was $965.0 million (down 8.41% YoY), and the FY2025 annual result was $965.0 million, down 8.41% from the prior year.
  • Cash & Current Investments was $965.0 million for Q4 2025 at Grifols, down from $1.1 billion in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $5.4 billion in Q4 2021 and troughed at $594.6 million in Q4 2023.
  • Average Cash & Current Investments over 5 years is $1.7 billion, with a median of $965.0 million recorded in 2025.
  • Year-over-year, Cash & Current Investments jumped 678.94% in 2021 and sank 88.77% in 2022.
  • Over 5 years, Cash & Current Investments stood at $5.4 billion in 2021, then tumbled by 88.77% to $604.7 million in 2022, then declined by 1.66% to $594.6 million in 2023, then soared by 77.2% to $1.1 billion in 2024, then decreased by 8.41% to $965.0 million in 2025.
  • Per Business Quant data, the three most recent Cash & Current Investments figures were $965.0 million in Q4 2025, $1.1 billion in Q4 2024, and $594.6 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Current Investments (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 5.28 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 22.05 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 9.39 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 7.94 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 5.70 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 12.04 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 7.64 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 13.08 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - 100.00 Mn
10 Grifols - - - 964.99 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 964.99 Mn
Dec 31, 2024 1.05 Bn
Dec 31, 2023 594.61 Mn
Dec 31, 2022 604.66 Mn
Dec 31, 2021 5.38 Bn
Dec 31, 2020 691.11 Mn
Dec 31, 2019 2.74 Bn
Dec 31, 2018 1.20 Bn
Dec 31, 2017 1.06 Bn
Dec 31, 2016 969.15 Mn
Dec 31, 2015 1.25 Bn
Dec 31, 2014 1.35 Bn
Dec 31, 2013 966.34 Mn
Sep 30, 2013 647.68 Mn
Jun 30, 2013 626.65 Mn
Mar 31, 2013 535.36 Mn
Dec 31, 2012 614.45 Mn
Sep 30, 2012 501.99 Mn
Jun 30, 2012 438.91 Mn
Mar 31, 2012 254.57 Mn